Drug intelligence / Profile preview

PLD-106

Development stage: Preclinical
Lead developer: Pelemed
Modality: Small Molecules

Overview

PLD-106 is a small molecule drug candidate currently in the discovery stage of development by the South Korean biotechnology company Pelemed. It is characterized as a wide-spectrum inhibitor intended for the treatment of solid tumors, specifically Renal Cell Carcinoma (RCC) and Hepatocellular Carcinoma (HCC). While the specific molecular targets have not been publicly disclosed beyond the broad-spectrum designation, the drug is being developed using Pelemed's proprietary medicinal chemistry platform, which focuses on the design of novel kinase inhibitors to overcome resistance in cancer treatment.

Beyond the preview

Go deeper on PLD-106.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PLD-106.

Explore the full profile